Get started with MyChoice CDx by downloading the provider product overview.
Whether you’ve heard about genetic testing before or want to learn more, we can help provide in-depth information on the test and your testing options.
MyChoice CDx is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in ASCO guidelines for selecting patients with ovarian cancer who may benefit from PARP inhibitors.1 By determining comprehensive HRD status, MyChoice CDx helps expand access to targeted therapy in both early and late-line settings.2
Knowing homologous recombination deficiency (HRD) status is essential in determining ovarian cancer treatment options. Nearly 50% of ovarian cancer patients are HRD+.4-6 Determining HRD status for ovarian cancer patients can help provide information on the magnitude of benefit for PARP inhibitor therapy and bring clarity in ovarian cancer treatment decisions.3
There is a critical need for integrated germline and tumor genomic testing in oncology, as up to 10% of germline mutations are missed through tumor testing alone.2
Determining HRD status through gene sequencing alone can miss critical causes, such as epigenetic events like BRCA1 promoter methylation and other measures of genomic instability.3,4 These limitations highlight the need for a more comprehensive approach to HRD assessment.
MyChoice CDx provides critical information to identify HRD+ patients who may benefit from PARP inhibitors, enabling more precise treatment decisions. This thorough methodology ensures no HRD cause is overlooked.
BRCA1 & BRCA2 status
Genomic instability score
MyChoice CDx can identify 34% more patients with HRD than other tumor tests that use %LOH alone2
Recognized by the American Society of Clinical Oncology (ASCO), MyChoice CDx is the only commercial HRD test endorsed for selecting patients with advanced ovarian cancer who may benefit from PARP inhibitor therapies.1
*MyChoice CDx received FDA-approved October 2019 with broad insurance coverage
A cohesive report with a simple summary of key findings to help prioritize critical insights while keeping comprehensive data readily available.
Provider completes the test request form (on the portal or paper TRF)
Myriad Genetics receives the TRF and sends a tumor specimen collection kit to the pathology lab
Tumor sample** arrives at Myriad Genetics lab and MyChoice CDx testing is performed*
Results are sent to the ordering provider (on the portal or in the mail)^
Tumor block is returned to the pathology lab immediately after result reporting (slides will not be returned)
*Upon receipt of tumor specimen **MyChoice CDx is run on formalin-fixed paraffin-embedded (FFPE) ovarian tumor tissue ^Results may be sent to the pathologist on the portal or in the mail
With Myriad Oncology, you can receive comprehensive results for germline testing, tumor genomic profiling, and HRD testing in one single ordering experience, getting clear, fast answers for your patients.
For a complete approach to ovarian cancer risk management and treatment planning, MyChoice CDx should be combined with MyRisk and Precise Tumor to deliver powerful results informing patient care across the entire journey-from assessing hereditary cancer syndromes to guiding treatment decisions.
Integrate germline and tumor genomic profiling with HRD testing to identify more patients most likely to benefit from PARP inhibitors. Precise Tumor and MyChoice deliver a powerful combination of actionable tumor genomic information and homologous recombination status, optimizing treatment strategies for ovarian cancers.
Combine HRD testing with tumor genomic profiling for a comprehensive view of all the available FDA-approved targeted therapies and immuno-oncology treatments options, as well as clinical trials most likely to benefit your patients with advanced ovarian cancer.
Every MyChoice CDx test delivers clear, actionable results, providing the critical information needed to guide ovarian cancer treatment decisions with confidence.
MyChoice CDx determines HRD status through a combined evaluation of BRCA1/2 variants and genomic instability score (GIS) to ensure no HRD cause is overlooked.
Transparent pricing for genetic results with financial assistance and other affordability options.
Myriad MyChoice® CDx is a next generation sequencing-based in vitro diagnostic test that assesses the qualitative detection and classification of single nucleotide variants, insertions and deletions, and large rearrangement variants in protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes and the determination of Genomic Instability Score (GIS), which is an algorithmic measurement of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-scale State Transitions (LST) using DNA isolated from formalinfixed paraffin embedded (FFPE) tumor tissue specimens.
The results of the test are used as an aid in identifying ovarian cancer patients with positive homologous recombination deficiency (HRD) status, who are eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes, or may become eligible, because of a positive test result for deleterious or suspected deleterious mutations in BRCA1 or BRCA2 genes or a positive Genomic Instability Score, for treatment with the targeted therapy listed in Table 1 in accordance with the most recently approved therapeutic product labeling.
* Refer to the drug label for HRD definition for olaparib monotherapy or combination therapy.
Detection of deleterious or suspected deleterious BRCA1 and BRCA2 mutations and/or positive Genomic Instability Score in ovarian cancer patients is also associated with enhanced progression-free survival (PFS) from Zejula® (niraparib) maintenance therapy in accordance with the most recently approved therapeutic product labeling. The MyChoice® CDx assay is for professional use only and is performed exclusively at Myriad Genetic Laboratories, Inc. site located in Salt Lake City, UT.
LYNPARZA is a registered trademark of the AstraZeneca group of companies.
Myriad Genetics, MyRisk, Precise Tumor, MyChoice, Prolaris, BRACAnalysis CDx, RiskScore, and their respective logos, are registered trademarks of Myriad Genetics, Inc. and its subsidiaries in the United States and other jurisdictions. EndoPredict and the EndoPredict logo are either trademarks or registered trademarks of Eurobio Scientific.